Mineralys Therapeutics (MLYS) is back in focus after the FDA accepted its New Drug Application for lorundrostat in adult hypertension and set a PDUFA action date of December 22, 2026.

Despite the NDA milestone, Mineralys Therapeutics’ recent share price performance has been weak, with a 30 day share price return showing an 8.5% decline and a 90 day share price return showing a 25.84% decline. However, its 1 year total shareholder return of 82.09% suggests longer term holders have still seen strong gains, so momentum has softened even as regulatory visibility has increased.

If this FDA news has you thinking about where else breakthrough treatments could emerge, you might want to scan our list of 32 healthcare AI stocks as a starting point for other potential ideas.

With shares soft in recent months, but a 1-year total return above 80% and the stock trading at a sizeable discount to the current analyst price target, are you looking at an opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 46.5% Undervalued

With Mineralys Therapeutics last closing at $27.24 against a narrative fair value of $50.88, the current gap rests heavily on future lorundrostat execution.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

Read the complete narrative. Read the complete narrative.

Want to understand what kind of revenue ramp and profit margin shift would need to materialize to support that valuation gap, and how long the transition from zero revenue to a full commercial profile is being modeled to take in this narrative? The answers sit in a detailed set of forecasts and assumptions that go well beyond a single hypertension indication and factor in broader cardiorenal use cases.

Result: Fair Value of $50.88 (UNDERVALUED)

However, you still need to weigh key risks, including the possibility of regulatory setbacks for lorundrostat or slower than expected uptake in a crowded aldosterone synthase inhibitor market.

Next Steps

Given the mix of enthusiasm and caution in this story, it makes sense to look at the numbers yourself and decide quickly where you stand. You can start with 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If this story has sharpened your focus, do not stop here. The next strong idea you add to your watchlist could be sitting in our screeners.

• Target quality at a discount by reviewing our list of 46 high quality undervalued stocks that pair business strength with prices below their estimated worth.
• Prioritise resilience by scanning 63 resilient stocks with low risk scores that score well on financial risk checks and may suit a steadier approach.
• Get ahead of the crowd by checking our screener containing 23 high quality undiscovered gems where solid fundamentals have yet to attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.